Aethlon Medical advances Hemopurifier study as final trial cohort nears completion

Aethlon Medical CEO James Frakes joined Steve Darling from Proactive to discuss the company’s Hemopurifier® technology and the progress of its ongoing clinical program evaluating the device’s potential role in cancer treatment. The Hemopurifier is an investigational medical device designed to remove harmful particles from the bloodstream. Frakes explained that the technology works alongside existing dialysis and blood-pumping systems, using a plant lectin-based mechanism to bind and remove viruses as well as cancer-associated extracellular vesicles (EVs), which are believed to play a role in tumor growth, immune suppression, and the spread of cancer. Aethlon has received two FDA Breakthrough Device Designations, one targeting life-threatening viral infections with no approved treatments and another focused on oncology applications. While the company initially concentrated on infectious diseases such as Ebola, Frakes said its primary development focus has now shifted toward cancer...